Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis

Author:

Rezagholizadeh AfraORCID,Khiali Sajad,Sarbakhsh Parvin,Entezari-Maleki Taher

Funder

U.S. Food and Drug Administration

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Pharmacology

Reference54 articles.

1. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease;Agostini;mBio,2018

2. Remdesivir use in patients with coronavirus COVID-19 disease: a systematic review and meta-analysis;Alexander;medRxiv,2020

3. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses;Amirian;One Health,2020

4. Hospital length of stay for severe COVID-19: implications for Remdesivir's value;Anderson;medRxiv,2020

5. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post_treatment hospitalisation status;Antinori;Pharmacol. Res.,2020

Cited by 85 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3